- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01240889
Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges* (Roche)
October 8, 2012 updated by: Creighton University
This study will be a randomized, double blind, placebo-controlled, parallel group study and will include subjects with ragweed-induced seasonal allergic rhinitis.
Study Overview
Detailed Description
The primary goal of this proposal is to assess the ability of an intranasal corticosteroid, fluticasone, and montelukast to affect the upper airway and systemic physiologic, biologic and clinical parameters occurring after an early and late upper airway allergic response to ragweed in ragweed allergic rhiniticsThe assessment of early allergy responses in the nose has been fairly well established in our laboratory and we will use methods detailed in previous publications (21, 23 24).
One potential challenge will be to sample upper airway mediators and cytokines without affecting clinical parameters such as symptom scores and acoustic rhinometry readings.
Moreover, we will need to sample at time points throughout six or more hours in order to accurately determine the effects on late phase allergic responses.
Nasal filter paper sampling is a technique that we are currently engaged in using, and we will work with Roche to elute the samples and measure multiple mediators and cytokines.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
- Creighton University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects aged 19-60 years.
- Females of child bearing potential must use appropriate birth control throughout the study and urine pregnancy tests must be negative prior to dosing at each study visit.
- Subjects with a documented history of ragweed-induced seasonal allergic rhinitis requiring pharmacotherapy during the preceding 2 allergen seasons.
- Subjects with a positive skin prick test to short ragweed (Amb a 1) extract, defined as >3mm wheal larger than saline control
- Subjects spirometry FEV1 must be > 80% predicted prior to each allergen challenge
- Subjects average post diluents nasal congestion score must be < 1 at admission for each study visit
Exclusion Criteria:
- Subjects with evidence or history of clinically significant medical illnesses other than changes related to allergic rhinitis. Subjects with some stable chronic medical conditions not expected to interfere with the conduct or safety of the study may be eligible to participate based on the investigator's discretion.
- Subjects with a history of asthma or urticaria, or a screening FEV1 prior to allergen challenge of <80% of predicted. in FEV1 compared to pre-diluent FEV1 baseline at either screening visit.
- Subjects with significant nasal deformity, recent nasal surgery nasal polyps or chronic rhinosinusitis.
- Subjects who have smoked in the last 6 months or have a history of >10 pack years.
- Subjects who are taking or have taken restricted concomitant medications that could confound the safety or efficacy assessments including those shown below.
- Subjects who have history or evidence of alcohol or drug abuse.
- Subjects exposed to cat and have a positive skin test to cat.
- Subjects that have a positive skin test to dust mite (D pteronyssinus/ D farinae) requiring pharmacotherapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: montelukast
luekotriene inhibitor
|
nasal spray
|
Active Comparator: Fluticasone
Nasal steroid
|
2 sprays per day in each nostril
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effect of nasal allergen challenges on biomarkers
Time Frame: December 2011
|
December 2011
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Thomas B Casale, MD, Creighton University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (Actual)
July 1, 2011
Study Completion (Actual)
July 1, 2011
Study Registration Dates
First Submitted
October 28, 2010
First Submitted That Met QC Criteria
November 10, 2010
First Posted (Estimate)
November 15, 2010
Study Record Updates
Last Update Posted (Estimate)
October 10, 2012
Last Update Submitted That Met QC Criteria
October 8, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-15912
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergy
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustUnknownEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
Hong Kong Sanatorium & HospitalChinese University of Hong KongTerminatedAllergy to Fish | Allergy to Shrimp | Allergy to CrabHong Kong
-
Martini Hospital GroningenRecruitingCow Milk Allergy | Food AllergyNetherlands
-
University GhentActive, not recruitingCow Milk Allergy | Food AllergyBelgium
-
Sayantani B. SindherNational Institute of Allergy and Infectious Diseases (NIAID)TerminatedAllergy;Food | Allergy to Shrimp | Allergy to Cashew Nut (Disorder)United States
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
-
Federico II UniversityUnknown
-
National Jewish HealthCompletedEgg Allergy | Peanut Allergy | Milk AllergyUnited States
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
Clinical Trials on Fluticasone
-
West Penn Allegheny Health SystemCompleted
-
GlaxoSmithKlineCompleted
-
University of FloridaFood and Drug Administration (FDA)Completed
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Germany, Romania, Russian Federation, Ukraine, Chile, Sweden, Mexico, Netherlands, Poland
-
GlaxoSmithKlineCompletedAsthmaGermany, Romania, Bulgaria, Chile, Russian Federation, South Africa, Estonia, Italy, Mexico, Greece, Hungary, Croatia, Brazil
-
University of DundeeCompletedAsthma | Allergic RhinitisUnited Kingdom
-
Imperial College LondonCompleted
-
University of MilanTerminatedBronchiectasis | Pulmonary Disease | Chronic BronchitisItaly